Neural Therapeutics, a Frankfurt Stock Exchange newbie, intends to enter Germany’s rapidly increasing cannabis sector with the acquisition of Hanf.com. Canadian company, known for its pioneering work in ethnobotanical drug research, is strategically expanding beyond its psychedelic roots with this acquisition, which marks an important entry into the commercial cannabis industry.
Neural Therapeutics: from psychedelics to profits
Neural Therapeutics used to focus on mental health. They worked with plant-based substances like mescaline, but now they apply their scientific experience. They are entering the commercial cannabis market. The corporation wants to merge its drug goals with a money-making plan. It plans to buy a majority stake in Hanf.com. First communication about Neural’s acquisition of Hanf.com were released in October 2024.
This move forms part of a larger strategy: generate short-term revenue while pursuing long-term goals in psychedelic therapy development. The acquisition consists of two steps: Neural plans to purchase 37% of Hanf.com‘s parent firm, CWE European Holdings Inc., and aims to increase its share to 100% upon meeting specific performance goals.
Hanf.com is a leader in Germany’s CBD market
Hanf.com is a well-known player in the German CBD and hemp product market, with 12 physical stores in Bavaria and a thriving online retail business. The company’s yearly revenues are anticipated to be around €4.8 million, and management expects operational viability by 2025.
Importantly, Hanf.com’s current infrastructure and customer base allow Neural Therapeutics to establish an immediate presence in Germany, one of Europe’s most promising cannabis markets. Unlike merely speculative projects, this acquisition provides tangible results—actual revenue, genuine consumers, and real assets.
This consistent CBD-based income is expected to provide an income source for Neural while it pursues clinical trials and medication development in the psychedelics field. It’s a hybrid model that combines short-term profitability and long-term innovation.
German cannabis market opportunities for Neural
Neural Therapeutics announced also that its shares have commenced trading on the Frankfurt Stock Exchange under the ticker symbol “M6B.” Deutsche Börse AG operates the Frankfurt Stock Exchange, which is a significant financial center for European and international investors and one of the world’s largest securities trading platforms.
Germany’s cannabis scene changed significantly in April 2024, when the government legalized recreational cannabis possession and home cultivation. Adults may now lawfully possess up to 25 grams of cannabis and cultivate up to three plants. Starting in July 2024, cannabis “clubs” of up to 500 members are able to grow and distribute cannabis together.
Medical cannabis, which was previously legal prior to these developments, has experienced an increase in demand. In 2024, medical cannabis sales reached an estimated €450 million, and imports surpassed 40 metric tons. Market analysts project this figure will more than double by the end of the decade, with annual revenue estimates exceeding $1 billion USD. These developments strengthen Germany’s role as a key player in the European cannabis industry. As restrictions shift and acceptance expands, consumer and investor interest will likely skyrocket, creating a favorable climate for companies like Neural Therapeutics.
Neural enters the German market after large international players like Aurora Cannabis and Tilray have already expanded there. Aurora has delivered its first domestically cultivated medical cannabis under the IndiMed brand. Tilray and Germany’s Demecan GmbH also hold licenses as farmers. Neural Therapeutics takes a unique approach. It combines commercial cannabis with a solid pharmaceutical pipeline. This sets it apart from larger competitors. Neural focuses on CBD retail and psychedelic medicine. This makes it adaptable. The industry values innovation. It also emphasizes regulatory compliance and scientific legitimacy.
Neural Therapeutics: long-term vision
While the Hanf.com acquisition provides a consistent cash stream and regional access, Neural’s primary goal remains plant-based therapies. The company is actively developing mescaline-based pharmaceuticals derived from the San Pedro cactus, with ambitions to seek FDA approval in the US and regulatory acceptability in Europe. Additionally, Neural Therapeutics Inc., a Toronto-based ethnobotanical drug discovery company that is committed to the development of therapeutic drugs for mental illnesses associated with substance use disorders, has now announced that it has submitted a patent application. The application is focused on the treatment of several significant mental health conditions with mescaline, as well as on the development of innovative technology for the extraction of mescaline for the production of pharmaceutical-grade products.
Neural is also investigating the nutraceuticals area, developing non-prescription supplements with possible wellness advantages based on ancient plant medicine. With clinical trials for psychedelic medicines on the horizon, Neural’s entry into the cannabis industry might act as a financial catalyst, as well as a branding and infrastructure move. By establishing a presence now, the company lays the framework for future product launches and a larger European reach.
Neural Therapeutics wants to buy Hanf.com. This is not just a deal, it is a shift in strategy. This acquisition blends innovation with commerce. It shows market foresight. The company enters Germany’s cannabis market. This move aims for quick revenue and future growth. It stays true to its ethnobotanical science roots.
As Germany becomes a major cannabis hub in Europe, Neural is aligning with industry trends and legal momentum. In addition, Neural Therapeutics has reinforced its intellectual property portfolio by filing a patent application. If successful, this strategy might propel Neural from a minor biotech company to a key player in the worldwide cannabis and psychedelics industries.